Market by Product Type, Therapeutic Application, and End-user | Forecast 2023-2028
Triton’s report predicts that the market for
botulinum toxin type A in Thailand will display a CAGR of 10.89% over the forecast period 2023-2028, attaining $XX million by 2028.
The pure botulinum toxin, also called botulinum toxin type A, is derived
from Clostridium botulinum bacteria. It acts by paralyzing and blocking the
release of acetylcholine at the neuromuscular junction. This toxin finds
applications in both medical and cosmetic fields, treating issues like crow’s
feet, glabellar lines, forehead wrinkles, abnormal muscle contractions, and
autonomic disorders such as sialorrhea, hyperhidrosis, and hypersalivation.
Recently, it has been used to treat myofascial
pain syndrome, tension headaches, and migraines. It is also used off-label for
several conditions, including neurogenic thoracic outlet syndrome, myofascial
pain, post-herpetic neuralgia, epicondylitis, post-stroke pain, trigeminal
neuralgia, diabetic neuropathy, etc.
The most popular preparation, botulinum toxin
type A, available in Thailand include Botox® (Allergan Pharmaceuticals),
Xeomin® (Merz Pharmaceuticals), Nabota (Daewoong Pharmaceutical Co Ltd),
Botulax (Hugel Pharma Inc), and Dysport® (Ipsen Pharmaceuticals). The Thailand
Food and Drug Administration (TFDA) is the national regulatory body and
competent authority responsible for registering, evaluating, and monitoring
food and drug products, including botulinum toxin.
Hospitals are increasing their investments. This
includes public hospitals, which have improved their services to compete with
those offered by the private sector. They also benefit from technological
prowess and a skilled workforce. Additionally, the inability of the public
healthcare system to keep up with the growing demand has opened up a market for
private healthcare providers, who often place a strong emphasis on the
promptness and convenience of their services. Such changes will likely impact
the botulinum toxin type A market in Thailand.
Triton Market Research’s report provides
in-depth insight into the Thailand botulinum toxin type A market, along with
segmentation analysis. The detailed analysis of the market includes PEST
analysis, current market trends, regulatory framework, and insurance system & reimbursements. The segmentation analysis
includes market by product type, therapeutic application, and end-user.
The
companies listed in the botulinum toxin type A market include Abbvie Inc, Merz
Pharma, Ipsen Pharma, and Hugel Inc.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. THAILAND
BOTULINUM TOXIN TYPE A MARKET – SUMMARY
1.1. MARKET
SIZE & FORECAST
1.2. COUNTRY
ANALYSIS
1.3. MARKET
DRIVING ASPECTS
1.3.1. GROWING
MEDICAL TOURISM
1.3.2. FAVORABLE
PARTNERSHIPS IN THE HEALTHCARE SECTOR
1.4. MARKET
RESTRAINING ASPECT
1.4.1. USE OF
UNAUTHORIZED INGREDIENTS AND PRODUCTS
2. THAILAND
BOTULINUM TOXIN TYPE A MARKET OUTLOOK
2.1. PEST
ANALYSIS
2.2. CURRENT
MARKET TRENDS
2.3. KEY
MARKET STRATEGIES
2.3.1. COLLABORATIONS
2.3.2. PRODUCT
LAUNCHES AND DEVELOPMENTS
2.3.3. ACQUISITIONS
2.4. POTENTIAL
FOR NEW ENTRANTS IN THAILAND BOTULINUM TYPE A MARKET
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. REGULATORY
FRAMEWORK
2.7. INSURANCE
SYSTEM AND REIMBURSEMENTS
2.7.1. HEALTHCARE
& INSURANCE SYSTEM
2.7.2. REIMBURSEMENT
FOR THERAPEUTIC BOTOX TREATMENT
3. THAILAND
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY PRODUCT TYPE
3.1. ABOBOTULINUMTOXIN
TYPE A
3.2. INCOBOTULINUMTOXIN
TYPE A
3.3. ONABOTULINUMTOXIN
TYPE A
4. THAILAND
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
4.1. CHRONIC
MIGRAINE
4.2. SPASTIC
DISORDERS
4.3. CERVICAL
DYSTONIA
4.4. DETRUSOR
OVERACTIVITY
4.5. OTHER
THERAPEUTIC APPLICATIONS
5. THAILAND
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY END-USER
5.1. HOSPITALS
AND CLINICS
5.2. OTHER
END-USERS
6. COMPETITIVE
LANDSCAPE
6.1. ABBVIE
INC
6.2. HUGEL
INC
6.3. IPSEN
PHARMA
6.4. MERZ
PHARMA
6.5. MEDYTOX
INC
6.6. DAEWOONG
PHARMACEUTICAL CO LTD
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE
1: REGULATORY FRAMEWORK FOR THAILAND BOTULINUM TOXIN TYPE A MARKET
TABLE
2: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2023-2028 (IN $
MILLION)
TABLE
3: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION,
2023-2028 (IN $ MILLION)
TABLE
4: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY END-USER, 2023-2028 (IN $
MILLION)
TABLE
5: LIST OF BOTULINUM TOXIN TYPE A MARKET COLLABORATIONS
TABLE
6: LIST OF BOTULINUM TOXIN TYPE A MARKET PRODUCT LAUNCHES & DEVELOPMENTS
TABLE
7: LIST OF BOTULINUM TOXIN TYPE A MARKET ACQUISITIONS
FIGURE
1: MARKET ATTRACTIVENESS INDEX
FIGURE
2: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2022 & 2028 (IN
%)
FIGURE
3: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY ABOBOTULINUMTOXIN TYPE A,
2023-2028 (IN $ MILLION)
FIGURE
4: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY INCOBOTULINUMTOXIN TYPE A,
2023-2028 (IN $ MILLION)
FIGURE
5: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY ONABOTULINUMTOXIN TYPE A,
2023-2028 (IN $ MILLION)
FIGURE
6: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2022
& 2030 (IN %)
FIGURE
7: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY CHRONIC MIGRAINE, 2023-2028 (IN $
MILLION)
FIGURE
8: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY SPASTIC DISORDERS, 2023-2028 (IN
$ MILLION)
FIGURE
9: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY CERVICAL DYSTONIA, 2023-2028 (IN
$ MILLION)
FIGURE
10: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY DETRUSOR OVERACTIVITY, 2023-2028
(IN $ MILLION)
FIGURE
11: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY OTHER THERAPEUTIC APPLICATIONS,
2023-2028 (IN $ MILLION)
FIGURE
12: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE
13: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY HOSPITALS AND CLINICS, 2023-2028
(IN $ MILLION)
FIGURE
14: THAILAND BOTULINUM TOXIN TYPE A MARKET, BY OTHER END-USERS, 2023-2028 (IN $
MILLION)